Menu
![]() ![]() ![]() FLT3 is highly expressed on dendritic cells, which are responsible for the stimulation of T cells. today announced that the company has acquired an exclusive worldwide license to a patent estate from Johns Hopkins University for treating immune-related disorders by inhibiting the FLT3 tyrosine kinase. Research project to focus on Xanthus’ novel class of FLT3 inhibitors for autoimmune diseasesĬAMBRIDGE, MA, USA | | Xanthus Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |